Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center

home / authors / yvonne-efebera,-md,-ohio-state-university-comprehensive-cancer-center

Articles

The Future of Multiple Myeloma

The Future of Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Targeted Treatment Options in Multiple Myeloma

Targeted Treatment Options in Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Trials in Relapsed/Refractory Multiple Myeloma

Trials in Relapsed/Refractory Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Treatment Options in Relapsed/Refractory Multiple Myeloma

Treatment Options in Relapsed/Refractory Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Options for Transplant Ineligible Patients in Multiple Myeloma

Options for Transplant Ineligible Patients in Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Maintenance Therapy in Multiple Myeloma

Maintenance Therapy in Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

The Role of Transplant in Multiple Myeloma

The Role of Transplant in Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Looking at GRIFFIN Trial Data

Looking at GRIFFIN Trial Data

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

A Look at the ENDURANCE Trial

A Look at the ENDURANCE Trial

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Introduction to Multiple Myeloma

Introduction to Multiple Myeloma

Thomas Martin, MD, University of California San Francisco;Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center
August 10th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data